Preterm Birth And Prom Testing Market Growth Insights and Analysis
Preterm Birth And Prom Testing Market |
The Preterm Birth And
Prom Testing Market is estimated to be valued at US$ 1.69 Bn in 2023 and is
expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as
highlighted in a new report published by Coherent Market Insights.
The Preterm Birth And Prom Testing Market is witnessing high growth owing to
Rising Prevalence of Preterm Birth. Preterm birth refers to any birth before 37
weeks of pregnancy are completed. Preterm birth complications are the leading
cause of death among children under 5 years of age. According to WHO, preterm
birth complications claim more than 1 million lives each year. Thus, rising
prevalence of preterm birth is fueling the growth of the preterm birth and prom
testing market.
Market Overview:
The preterm birth and prom testing market comprises testing kits and devices
used for detecting the risk of preterm birth. These include fetal fibronectin
tests, phazyme-point of care tests, ultrasound imaging, uterine monitoring, and
biochemical tests. Growing awareness about the complications of preterm birth
and advantages of early diagnosis and management are driving the growth of this
market.
Market key trends:
The rising adoption of point-of-care testing is a key trend in the preterm
birth and prom testing market. Point-of-care testing provides fetal fibronectin
and phazyme testing at the bedside, with quick and easy-to-use assays. This
eliminates the need to send samples to the laboratory and waiting for the
results. Moreover, it enables timely clinical decision-making and early
intervention. Point-of-care testing kits are user-friendly, require minimal
training, and provide accurate and rapid results. This increases convenience
and accessibility of preterm birth risk assessment. As a result, point-of-care
testing solutions are gaining increasing preference over conventional
laboratory tests.
Porter’s Analysis
Threat of new entrants: The preterm birth and prom testing market has moderate
threat of new entrants due to established brands, requirements for research and
development and regulatory approvals.
Bargaining power of buyers: Buyers have moderate bargaining power due to
availability of substitutes and price sensitivity of customers.
Bargaining power of suppliers: Suppliers have low to moderate bargaining power
due to availability of substitute raw materials and suppliers.
Threat of new substitutes: Threat of new substitutes is low as preterm birth
and prom testing are essential medical diagnostic tools.
Competitive rivalry: High due to presence of many global and local players.
SWOT Analysis
Strength: Availability of advanced screening tests with high accuracy and
minimal risk of false positive results. Growing awareness about availability of
preterm birth screening.
Weakness: High cost of advanced diagnostic tests limits their widespread
adoption. Lack of awareness in low income regions.
Opportunity: Rapidly growing geriatric population prone to preterm births
presents an opportunity. Untapped growth potential in developing regions.
Threats: Stringent regulatory approvals delay market entry of new players.
Reimbursement issues hamper revenue growth.
Key Takeaways
Global
Preterm Birth And Prom Testing Market Demand is expected to witness
high growth at a CAGR of 12% over
the forecast period, due to increasing awareness about negative health impact
of preterm births.
Regional analysis: North America dominates the preterm birth and prom testing
market currently due to availability of advanced healthcare facilities and
favorable reimbursement policies. Asia Pacific is expected to be the fastest
growing market due to rising healthcare spending and improving medical
infrastructure.
Key players: Key players operating in the preterm birth and prom testing market
are Abbott Laboratories, Biosynex, Qiagen Sciences LLC, Clinical Innovations
LLC, Sera Prognostics, The Cooper Companies Inc., Medixbiochemica, Hologic
Inc., IQ Products, NX Prenatal Inc., Promega Corporation, Medical Predictive
Technologies Inc., Biosynex, Clinical Innovations LLC, NX Prenatal Inc.,
Medixbiochemica, Qiagen Sciences LLC, Sera Prognostics Inc., Insight
Pharmaceuticals LLC, Creative Diagnostics.
Read More- https://www.dailyprbulletin.com/preterm-birth-and-prom-testing-market-value-insights-and-forecast/
Comments
Post a Comment